Regulatory Updates
🇺🇸 FDA Page 26FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Showing 301–312 of 373 articles
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
M&A in Pharmaceuticals: Bigger, Bolder, and Far More Strategic
Enhertu's Dual FDA Approvals: A Game Changer in Early Breast Cancer Treatment
NICE Approves Imfinzi for Stomach Cancer: What It Means for Investors
UCB Acquires Antibody Treatment Maker: Implications for Autoimmune Disease Market
Big Pharma M&A Set for Mega Year Amid Patent Expiries
Leadership Changes at CDER and CBER: Implications for Oncology
FDA Shake-Up: Implications for Oncology and Beyond
Pharma M&A Round-Up: April 2026 Insights and Analysis
Regulatory Round-Up: Key FDA Approvals for Cancer Drugs
10 Clinical Trials to Watch in the First Half of 2026
FDA Leadership Changes Crisis: Implications for Drug Approvals